臨床試驗市場規模、佔有率、按服務類型、階段、方式、治療領域、交付模式和地區分類的成長分析 - 2025-2032 年產業預測

2023 年臨床試驗市場規模價值 813 億美元，預計將從 2024 年的 865.8 億美元成長到 2032 年的 1,433 億美元，預測期內（2025-2032 年）的複合年成長率為 6.5%。

臨床試驗市場正在經歷顯著成長，原因包括新興市場臨床試驗數量的增加、製藥公司研發投入的活性化以及疾病（尤其是罕見疾病和孤兒病）盛行率的上升。糖尿病等疾病正在推動對創新療法的需求，預計治療方法年 20-79 歲人群將受其影響，而到 2045 年這一數字可能會上升至 7.837 億。此外，歐盟委員會於 2022 年 1 月啟動的「加速歐盟臨床試驗」等政府舉措旨在簡化臨床試驗流程，提升歐洲作為臨床研究中心的地位。這種支持性環境正在推動全球產業的發展，並促進安全有效藥物的開發。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管分析
• 技術分析
• 案例研究

臨床試驗市場規模（按服務類型和複合年成長率） (2025-2032)

• 市場概覽
• 臨床試驗管理與監控
• 化驗服務
  • 分析測試服務
  • 生物分析測試服務
• 臨床試驗資料管理服務
  • 生物統計學
  • 其他資料管理服務
• 臨床試驗供應和物流服務
• 諮詢
• 患者招募和保留
• 醫學寫作
• 安全和藥物警戒
• 其他服務類型

臨床試驗市場規模（分階段）及複合年成長率（2025-2032）

• 市場概覽
• 第三階段
• 第二階段
• 第一階段
• 第四階段

臨床試驗市場規模（依模式分類）及複合年成長率（2025-2032）

• 市場概覽
• 小分子
• 生物製藥
• 醫療設備和體外診斷

臨床試驗市場規模（依治療領域分類）及複合年成長率（2025-2032）

• 市場概覽
• 腫瘤學
• 神經病學
• 呼吸系統疾病
• 代謝疾病/內分泌學
• 心血管疾病
• 皮膚科
• 消化系統疾病
• 免疫疾病
• 感染疾病
• 精神病學
• 眼科
• 血液學
• 泌尿生殖系統與婦女健康
• 其他治療領域

臨床試驗市場規模（按交付模式和複合年成長率） (2025-2032)

• 市場概覽
• 全方位服務外包（FSO）模式
• 功能服務供應商（FSP）模型
• 混合模式

臨床試驗市場規模（依研究設計及複合年成長率） (2025-2032)

• 市場概覽
• 侵入性
• 觀察性

臨床試驗市場規模（按最終用戶和複合年成長率） (2025-2032)

• 市場概覽
• 製藥和生物製藥公司
• 醫療設備公司
• 學術機構

各地區臨床試驗市場規模及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Thermo Fisher Scientific, Inc.（US）
• IQVIA, Inc.（US）
• ICON plc（Ireland）
• Laboratory Corporation of America Holdings（US）
• Syneos Health（US）
• Charles River Laboratories（US）
• Fortrea, Inc.（US）
• SGS（Switzerland）
• ACM Global Laboratories（US）
• Advanced Clinical（US）
• PSI（Switzerland）
• BioAgile（India）
• Pepgra（India）
• CTI Clinical Trial and Consulting Services（US）
• Dove Quality Solutions（UK）
• Firma Clinical Research（US）

結論和建議

Clinical Trials Market size was valued at USD 81.3 billion in 2023 and is poised to grow from USD 86.58 billion in 2024 to USD 143.3 billion by 2032, growing at a CAGR of 6.5% during the forecast period (2025-2032).

The Clinical Trials Market is experiencing significant growth driven by various factors, including increased clinical trials in emerging markets, heightened R&D investment by pharmaceutical companies, and the rising prevalence of diseases, especially rare and orphan diseases. Conditions such as diabetes, which affected an estimated 536.6 million individuals aged 20 to 79 in 2021 and may rise to 783.7 million by 2045, are intensifying the demand for innovative therapies. Additionally, government initiatives, like the European Commission's Accelerating Clinical Trials in the EU program launched in January 2022, aim to streamline trial processes and enhance Europe's standing as a hub for clinical research. This supportive environment bolsters global industry growth, driving advancements in safe and effective pharmaceutical development.

Top-down and bottom-up approaches were used to estimate and validate the size of the Clinical Trials market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Clinical Trials Market Segments Analysis

Global Clinical Trials Market is segmented by Service Type, Phase, Modality, Therapeutic Area, Delivery Model, Study Design, End User and region. Based on Service Type, the market is segmented into Clinical Trial Management & Monitoring, Laboratory Services, Clinical Trial Data Management Services, Clinical Trial Supply & Logistic Services, Consulting, Patient Recruitment & Retention, Medical Writing, Safety & Pharmacovigilance and Other Service Types. Based on Phase, the market is segmented into Phase III, Phase II, Phase I and Phase IV. Based on Modality, the market is segmented into Small Molecules, Biologics and Medical Devices & IVD. Based on Therapeutic Area, the market is segmented into Oncology, Neurology, Respiratory Disorders, Metabolic Disorders/Endocrinology, Cardiovascular System Disorders, Dermatology, Gastrointestinal Diseases, Immunological Disorders, Infectious Diseases, Psychiatry, Ophthalmology, Hematology, Genitourinary & Women's Health and Other Therapeutic Areas. Based on Delivery Model, the market is segmented into Full-Service Outsourcing (FSO) Model, Functional Service Provider (FSP) Model and Hybrid Model. Based on Study Design, the market is segmented into Interventional and Observational. Based on End User, the market is segmented into Pharmaceutical & Biopharmaceutical Companies, Medical Device Companies and Academic Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Clinical Trials Market

The growth of the Clinical Trials market is significantly propelled by increased investments in research and development by biotechnology and pharmaceutical companies. To successfully develop and launch new therapies, these organizations must meticulously design clinical trials. A surge in both public and private funding enables them to implement larger-scale research projects that enhance the safety and efficacy evaluations of new drugs. Such financial backing expedites the medication approval process and ultimately improves patient access to innovative treatments. Additionally, this investment fosters the discovery of new therapies while elevating the standards of clinical research, thus driving overall market growth.

Restraints in the Clinical Trials Market

Regulatory challenges significantly hinder the clinical trials market, often causing substantial delays in research and development due to difficulties in obtaining necessary approvals. Regulatory bodies like the FDA and EMA impose stringent requirements that necessitate meticulous documentation and adherence to Good Clinical Practice (GCP), along with comprehensive safety measures. These stringent regulations can be particularly burdensome for smaller firms, which may be deterred from initiating clinical studies due to the high costs associated with regulatory compliance. Additionally, varying national regulations in multi-national trials complicate the process further, slowing progress and limiting access to a diverse range of patient populations.

Market Trends of the Clinical Trials Market

The clinical trials market is witnessing a significant shift towards decentralized clinical trials (DCTs), driven by advancements in technology that enable virtual participation and remote patient monitoring. This trend enhances accessibility and flexibility for participants, ultimately fostering higher engagement through the use of wearable devices, telemedicine, and mobile health applications. As DCTs reduce travel-related costs and streamline data collection, they facilitate more efficient patient recruitment and retention, thereby expediting the overall clinical trial process. This evolution not only promises improved patient experiences but also holds the potential to transform the landscape of clinical research, making it more adaptive to modern healthcare needs.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Technology Analysis
• Case Studies

Global Clinical Trials Market Size by Service Type & CAGR (2025-2032)

• Market Overview
• Clinical Trial Management & Monitoring
• Laboratory Services
  • Analytical Testing Services
  • Bioanalytical Testing Services
• Clinical Trial Data Management Services
  • Biostatistics
  • Other Data Management Services
• Clinical Trial Supply & Logistic Services
• Consulting
• Patient Recruitment & Retention
• Medical Writing
• Safety & Pharmacovigilance
• Other Service Types

Global Clinical Trials Market Size by Phase & CAGR (2025-2032)

• Market Overview
• Phase III
• Phase II
• Phase I
• Phase IV

Global Clinical Trials Market Size by Modality & CAGR (2025-2032)

• Market Overview
• Small Molecules
• Biologics
• Medical Devices & IVD

Global Clinical Trials Market Size by Therapeutic Area & CAGR (2025-2032)

• Market Overview
• Oncology
• Neurology
• Respiratory Disorders
• Metabolic Disorders/Endocrinology
• Cardiovascular System Disorders
• Dermatology
• Gastrointestinal Diseases
• Immunological Disorders
• Infectious Diseases
• Psychiatry
• Ophthalmology
• Hematology
• Genitourinary & Women's Health
• Other Therapeutic Areas

Global Clinical Trials Market Size by Delivery Model & CAGR (2025-2032)

• Market Overview
• Full-Service Outsourcing (FSO) Model
• Functional Service Provider (FSP) Model
• Hybrid Model

Global Clinical Trials Market Size by Study Design & CAGR (2025-2032)

• Market Overview
• Interventional
• Observational

Global Clinical Trials Market Size by End User & CAGR (2025-2032)

• Market Overview
• Pharmaceutical & Biopharmaceutical Companies
• Medical Device Companies
• Academic Institutes

Global Clinical Trials Market Size & CAGR (2025-2032)

• North America (Service Type, Phase, Modality, Therapeutic Area, Delivery Model, Study Design, End User)
  • US
  • Canada
• Europe (Service Type, Phase, Modality, Therapeutic Area, Delivery Model, Study Design, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Service Type, Phase, Modality, Therapeutic Area, Delivery Model, Study Design, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Service Type, Phase, Modality, Therapeutic Area, Delivery Model, Study Design, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Service Type, Phase, Modality, Therapeutic Area, Delivery Model, Study Design, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Thermo Fisher Scientific, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IQVIA, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ICON plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Laboratory Corporation of America Holdings (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syneos Health (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fortrea, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SGS (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ACM Global Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Advanced Clinical (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PSI (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioAgile (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pepgra (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CTI Clinical Trial and Consulting Services (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dove Quality Solutions (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Firma Clinical Research (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations